Stanford study finds no conclusive benefit from treating kleptomania

A small clinical trial of a medication to treat kleptomania has failed to find any conclusive benefit for patients with the impulsive stealing disorder, according to researchers at the Stanford University School of Medicine.

But the results leave open the possibility that some medications, including the one in the trial, may still be an effective treatment for certain patients.

More than 1.2 million people in the United States are thought to suffer from kleptomania, the guilt-ridden, impulsive stealing of inexpensive and unneeded items. The condition differs from shoplifting, in which the action is usually planned and motivated by need or monetary gain. People suffering from kleptomania often fail to seek treatment for fear of legal repercussions.

The medication in the trial was escitalopram, marketed as Lexapro. The drug belongs to a class of antidepressants known as selective serotonin reuptake inhibitors, and earlier studies have suggested that SSRIs can be effective in treating some impulse control disorders, such as skin picking. In an earlier, non-blinded open-label phase of the kleptomania study, when trial participants were aware that they were taking escitalopram and not a placebo, 78 percent of the patients responded to the drug.

In the second phase of the study, conducted as a double-blind, placebo-controlled trial, the benefit was not seen.

"When we randomized people to drug vs. placebo, the same proportion of people relapsed on drug as relapsed on placebo, suggesting that it was really a placebo response in the initial phase of the study," said Lorrin Koran, MD, professor of psychiatry and behavioral sciences and first author of the study, which will be published in the March issue of the Journal of Clinical Psychiatry.

In the double-blind trial, 15 subjects were assigned to receive either a placebo or escitalopram. For both groups, the relapse rates were effectively the same, with three of seven patients on the drug relapsing, compared with four of eight on the placebo.

Koran says that the small number of subjects in the study makes it impossible to know with certainty whether the results of the trial are really indicative of the effectiveness of escitalopram.

"For some people, I think these drugs really do work. And for others, maybe not, but until you have large studies you can't tease that out," he said.

Koran emphasized that the results of the clinical trial are not definitive, and some people may be helped by therapy involving medication. For others, receiving psychological treatment, perhaps in combination with medication, may prove most effective. But regardless, he said, "People with this disorder should definitely seek treatment."

Source: Stanford University Medical Center

Related stories:

Common virus may serve as target for vaccine in fight against deadly brain tumors
By targeting a common virus, doctors may be able to extend the lives of patients diagnosed with the most prevalent and deadly type of brain tumor, according to a study led by researchers in Duke’s Preston Robert Tisch Brain Tumor Center.
HIV infection stems from few viruses
A new study reveals the genetic identity of human immunodeficiency virus (HIV), the version responsible for sexual transmission, in unprecedented detail.
Targeted therapy plus chemotherapy may pack 1-2 punch against melanoma
By targeting and disabling a protein frequently found in melanoma tumors, doctors may be able to make the cancer more vulnerable to chemotherapy, according to a new study by researchers in the Duke Comprehensive Cancer Center.
Scientists are building database of bite marks
(AP) -- It has sent innocent men to death row, given defense attorneys fits and splintered the scientific community. For a decade now, attorneys and even some forensic experts have ridiculed the use of bite marks to identify criminals as sham science and glorified guesswork.
Aprotinin associated with increased risk of death
Aprotinin is associated with a 50 per cent increase in the relative risk of death, according to a major Canadian clinical trial comparing three drugs routinely used to prevent blood loss during heart surgery. The trial, published in the New England Journal of Medicine, shows that approximately six per cent of patients who received aprotinin died within 30 days of surgery compared to four per cent of patients who received tranexamic acid or aminocaproic acid.
New treatment for hepatitis C
Researchers at the University of Oklahoma Health Sciences Center have found a new use for an old drug. Their findings appear online in the American Journal of Gastroenterology.
Prism glasses expand the view for patients with hemianopia
Innovative prism glasses can significantly improve the vision and the daily lives of patients with hemianopia, a condition that blinds half the visual field in both eyes. The peripheral prism glasses, which were invented by Dr. Eli Peli, a Senior Scientist at Schepens Eye Research Institute, were evaluated in the first community-based multi-center trial of such a device, which is published in the May issue of the Archives of Ophthalmology. The study was coordinated by Dr. Alex Bowers, a Senior Scientific Associate at the Institute.
Justice in the brain: Equity and efficiency are encoded differently
Which is better, giving more food to a few hungry people or letting some food go to waste so that everyone gets a share? A study appearing this week in Science finds that most people choose the latter, and that the brain responds in unique ways to inefficiency and inequity.

News discussion:

Medicine & Health news